PD-1/PD-L1 blocking antibodies have become standard treatment of various cancer types, including melanoma, NSCLC, mismatch repair-deficient and/or microsatellite-instable colorectal cancer, triple-negative breast cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, and several other cancers (37). This evidence concerns the gene CD274 and cancer.